Development of Potent Bifunctional Endomorphin-2 Analogues with Mixed μ-/δ-Opioid Agonist and δ-Opioid Antagonist Properties-Reference-Cited by-同舟云学术

Development of Potent Bifunctional Endomorphin-2 Analogues with Mixed μ-/δ-Opioid Agonist and δ-Opioid Antagonist Properties

Published:2004-05-28 Issue:14 Volume:47 Page:3591-3599
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Fujita Yoshio¹,Tsuda Yuko¹,Li Tingyou¹,Motoyama Takashi¹,Takahashi Motohiro¹,Shimizu Yoshiro¹,Yokoi Toshio¹,Sasaki Yusuke¹,Ambo Akihiro¹,Kita Atsuko¹,Jinsmaa Yunden¹,Bryant Sharon D.¹,Lazarus Lawrence H.¹,Okada Yoshio¹

Affiliation:

1. Department of Medicinal Chemistry, Faculty of Pharmaceutical Sciences and High Technology Research Center, Kobe Gakuin University, Nishi-ku, Kobe 651-2180, Japan, Department of Biochemistry, Tohoku Pharmaceutical University, 4-1, Komatsushima 4-chome, Aoba-ku, Sendai 981-8558, Japan, Department of Pharmacology I, Discovery Research Laboratories, Dainippon Pharmaceutical Co., Ltd., Enoki 33-94, Suita 564-0053, Japan, and Medicinal Chemistry Group, LCBRA, National Institute of Environmental Health Sciences...

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/jm030649p

Reference54 articles.

1. Comments on the optical and radio detection of black hole explosions

Cited by 54 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Peptidomimetics and Their Applications for Opioid Peptide Drug Discovery;Biomolecules;2022-09-05

2. An investigation of chiral diamides as organocatalysts in asymmetric aldol reaction;Journal of Heterocyclic Chemistry;2022-03-03

3. An Efficient Greener Approach for N-acylation of Amines in Water Using Benzotriazole Chemistry;Molecules;2020-05-28

4. Amine Activation:N-Arylamino Acid Amide Synthesis from Isothioureas and Amino Acids;Advanced Synthesis & Catalysis;2017-06-14

5. Targeting delta opioid receptors for pain treatment: drugs in phase I and II clinical development;Expert Opinion on Investigational Drugs;2017-01-02